South Korea · Delayed Price · Currency is KRW Daehan Nupharm Statistics
Total Valuation
Daehan Nupharm has a market cap or net worth of KRW 79.58 billion. The enterprise value is 153.75 billion.
| Market Cap | 79.58B |
| Enterprise Value | 153.75B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Daehan Nupharm has 14.04 million shares outstanding.
| Current Share Class | 14.04M |
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 39.76% |
| Owned by Institutions (%) | 0.33% |
| Float | 8.17M |
Valuation Ratios
The trailing PE ratio is 5.08.
| PE Ratio | 5.08 |
| Forward PE | n/a |
| PS Ratio | 0.39 |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 40.69 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 9.81 |
| EV / Sales | 0.75 |
| EV / EBITDA | 10.34 |
| EV / EBIT | 14.67 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.57 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 7.17 |
| Debt / FCF | -2.59 |
| Interest Coverage | 6.18 |
Financial Efficiency
Return on equity (ROE) is 11.85% and return on invested capital (ROIC) is 5.08%.
| Return on Equity (ROE) | 11.85% |
| Return on Assets (ROA) | 2.60% |
| Return on Invested Capital (ROIC) | 5.08% |
| Return on Capital Employed (ROCE) | 5.31% |
| Weighted Average Cost of Capital (WACC) | 2.88% |
| Revenue Per Employee | 900.83M |
| Profits Per Employee | 68.76M |
| Employee Count | 228 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 2.81 |
Taxes
| Income Tax | -513.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.90% in the last 52 weeks. The beta is 0.15, so Daehan Nupharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -24.90% |
| 50-Day Moving Average | 6,505.40 |
| 200-Day Moving Average | 6,706.25 |
| Relative Strength Index (RSI) | 34.66 |
| Average Volume (20 Days) | 51,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daehan Nupharm had revenue of KRW 205.39 billion and earned 15.68 billion in profits. Earnings per share was 1,116.99.
| Revenue | 205.39B |
| Gross Profit | 89.76B |
| Operating Income | 10.62B |
| Pretax Income | 15.16B |
| Net Income | 15.68B |
| EBITDA | 15.00B |
| EBIT | 10.62B |
| Earnings Per Share (EPS) | 1,116.99 |
Balance Sheet
The company has 33.38 billion in cash and 107.55 billion in debt, with a net cash position of -74.17 billion or -5,284.34 per share.
| Cash & Cash Equivalents | 33.38B |
| Total Debt | 107.55B |
| Net Cash | -74.17B |
| Net Cash Per Share | -5,284.34 |
| Equity (Book Value) | 138.21B |
| Book Value Per Share | 9,847.32 |
| Working Capital | 43.02B |
Cash Flow
In the last 12 months, operating cash flow was 1.96 billion and capital expenditures -43.54 billion, giving a free cash flow of -41.58 billion.
| Operating Cash Flow | 1.96B |
| Capital Expenditures | -43.54B |
| Depreciation & Amortization | 4.38B |
| Net Borrowing | 37.03B |
| Free Cash Flow | -41.58B |
| FCF Per Share | -2,962.55 |
Margins
Gross margin is 43.70%, with operating and profit margins of 5.17% and 7.63%.
| Gross Margin | 43.70% |
| Operating Margin | 5.17% |
| Pretax Margin | 7.38% |
| Profit Margin | 7.63% |
| EBITDA Margin | 7.30% |
| EBIT Margin | 5.17% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.76%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.76% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.95% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.76% |
| Earnings Yield | 19.70% |
| FCF Yield | -52.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Daehan Nupharm has an Altman Z-Score of 1.84 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 3 |